NS Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
Home » whitepapers » Interview with Dr David Orloff

White Paper

Interview with Dr David Orloff

Close Concerns recently had the distinct honor of discussing the recent FDA cardiovascular risk assessment guidelines for diabetes drugs with Dr. David Orloff, the former director of the division of metabolism and endocrinology products at FDA, and currently executive director of regulatory affairs at Medpace, Inc.

Download to find out more.

Download White Paper